EMERGENT BIOSOLUTIONS INC. (EBS) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
47/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseEBS / S&P 0.96% / 15.20% |
LoseEBS / S&P -9.56% / 15.00% |
LoseEBS / S&P -241.06% / 50.40% |
| 2026-Q10/3 |
LoseEBS / S&P -32.85% / -4.33% |
LoseEBS / S&P -29.89% / 11.30% |
LoseEBS / S&P -92.59% / 27.70% |
| 2025-Q41/3 |
WinEBS / S&P 40.14% / 2.65% |
LoseEBS / S&P -28.81% / 9.00% |
LoseEBS / S&P -124.73% / 13.40% |
| 2025-Q31/3 |
WinEBS / S&P 38.24% / 8.12% |
LoseEBS / S&P -29.91% / 4.61% |
LoseEBS / S&P -132.51% / 13.45% |
| 2025-Q21/3 |
WinEBS / S&P 31.28% / 10.94% |
LoseEBS / S&P -22.74% / 4.83% |
LoseEBS / S&P -122.02% / 10.63% |
| 2025-Q10/3 |
LoseEBS / S&P -49.16% / -4.27% |
LoseEBS / S&P -18.56% / 4.98% |
LoseEBS / S&P -75.34% / 10.57% |
| 2024-Q41/3 |
WinEBS / S&P 14.49% / 2.41% |
LoseEBS / S&P -0.54% / 5.25% |
LoseEBS / S&P -74.92% / 6.15% |
| 2024-Q31/3 |
WinEBS / S&P 22.43% / 5.89% |
LoseEBS / S&P 2.05% / 5.89% |
LoseEBS / S&P -73.64% / 6.11% |
| 2024-Q21/3 |
WinEBS / S&P 169.57% / 4.28% |
LoseEBS / S&P 2.79% / 5.38% |
LoseEBS / S&P -6.61% / 5.12% |
| 2024-Q12/3 |
LoseEBS / S&P 5.42% / 10.56% |
WinEBS / S&P 21.33% / 5.71% |
WinEBS / S&P 39.31% / 5.59% |
| 2023-Q41/3 |
LoseEBS / S&P -29.41% / 11.69% |
LoseEBS / S&P -6.10% / 6.81% |
WinEBS / S&P 249.76% / 7.78% |
| 2023-Q30/3 |
LoseEBS / S&P -53.74% / -3.27% |
LoseEBS / S&P -26.05% / 7.52% |
LoseEBS / S&P -4020.51% / -5.03% |
| 2023-Q20/3 |
LoseEBS / S&P -29.05% / 8.74% |
LoseEBS / S&P -32.15% / 9.50% |
LoseEBS / S&P -881.70% / -8.57% |
| 2023-Q10/3 |
LoseEBS / S&P -12.28% / 7.50% |
LoseEBS / S&P -43.70% / 10.77% |
LoseEBS / S&P -393.28% / -15.69% |
| 2022-Q40/3 |
LoseEBS / S&P -43.74% / 7.56% |
LoseEBS / S&P -36.99% / 11.88% |
LoseEBS / S&P -204.69% / -17.99% |
| 2022-Q30/3 |
LoseEBS / S&P -32.38% / -4.88% |
LoseEBS / S&P -9.75% / 13.47% |
LoseEBS / S&P -90.71% / -1.41% |
| 2022-Q20/3 |
LoseEBS / S&P -24.40% / -16.10% |
LoseEBS / S&P -7.50% / 13.71% |
LoseEBS / S&P -72.38% / 11.04% |
| 2022-Q10/3 |
LoseEBS / S&P -5.54% / -4.60% |
LoseEBS / S&P 1.73% / 15.97% |
LoseEBS / S&P -62.67% / 42.23% |
| 2021-Q40/3 |
LoseEBS / S&P -13.18% / 11.03% |
LoseEBS / S&P 14.03% / 15.00% |
LoseEBS / S&P -28.45% / 96.40% |
| 2021-Q31/3 |
LoseEBS / S&P -20.51% / 0.58% |
WinEBS / S&P 24.00% / 10.77% |
LoseEBS / S&P 35.05% / 69.42% |
| 2021-Q22/3 |
LoseEBS / S&P -32.20% / 8.55% |
WinEBS / S&P 35.69% / 6.58% |
WinEBS / S&P 72.59% / 51.81% |
| 2021-Q12/3 |
LoseEBS / S&P 3.69% / 6.17% |
WinEBS / S&P 53.99% / -1.06% |
WinEBS / S&P 452.31% / 7.39% |
| 2020-Q42/3 |
LoseEBS / S&P -13.29% / 12.15% |
WinEBS / S&P 40.65% / -3.72% |
WinEBS / S&P 449.51% / -33.42% |
| 2020-Q33/3 |
WinEBS / S&P 30.67% / 8.93% |
WinEBS / S&P 31.13% / -2.04% |
WinEBS / S&P 4342.86% / -27.10% |
| 2020-Q22/3 |
WinEBS / S&P 36.67% / 20.54% |
WinEBS / S&P 43.41% / -0.46% |
LoseEBS / S&P -1017.14% / -27.11% |
| 2020-Q13/3 |
WinEBS / S&P 7.25% / -19.60% |
WinEBS / S&P 29.55% / 3.47% |
WinEBS / S&P 60.49% / -14.75% |
| 2019-Q41/3 |
LoseEBS / S&P 3.19% / 9.07% |
WinEBS / S&P 41.37% / 5.36% |
LoseEBS / S&P -15.57% / 2.99% |
| 2019-Q32/3 |
WinEBS / S&P 8.22% / 1.70% |
WinEBS / S&P 44.07% / 5.02% |
LoseEBS / S&P -96.45% / 0.21% |
| 2019-Q21/3 |
LoseEBS / S&P -4.37% / 4.30% |
WinEBS / S&P 28.89% / 6.64% |
LoseEBS / S&P -115.63% / 8.65% |
| 2019-Q11/3 |
LoseEBS / S&P -14.78% / 13.65% |
WinEBS / S&P 52.20% / 8.12% |
LoseEBS / S&P -40.88% / 14.29% |
| 2018-Q42/3 |
WinEBS / S&P -9.95% / -13.52% |
WinEBS / S&P 39.47% / 9.05% |
LoseEBS / S&P -28.24% / 18.23% |
| 2018-Q32/3 |
WinEBS / S&P 30.38% / 7.71% |
WinEBS / S&P 35.99% / 10.21% |
LoseEBS / S&P 10.06% / 19.06% |
| 2018-Q22/3 |
LoseEBS / S&P -4.10% / 3.43% |
WinEBS / S&P 33.00% / 9.03% |
WinEBS / S&P 43.59% / 14.46% |
| 2018-Q13/3 |
WinEBS / S&P 13.30% / -0.76% |
WinEBS / S&P 11.77% / 7.68% |
WinEBS / S&P 16.10% / 12.46% |
| 2017-Q43/3 |
WinEBS / S&P 14.88% / 6.64% |
WinEBS / S&P 14.75% / 7.03% |
WinEBS / S&P 61.90% / 13.82% |
| 2017-Q32/3 |
WinEBS / S&P 19.29% / 4.48% |
LoseEBS / S&P 4.40% / 5.68% |
WinEBS / S&P 79.00% / 17.57% |
| 2017-Q21/3 |
WinEBS / S&P 16.77% / 3.09% |
LoseEBS / S&P -0.03% / 4.83% |
LoseEBS / S&P 16.42% / 17.74% |
| 2017-Q10/3 |
LoseEBS / S&P -11.57% / 6.07% |
LoseEBS / S&P -8.14% / 3.67% |
LoseEBS / S&P -38.86% / 13.32% |
| 2016-Q41/3 |
WinEBS / S&P 4.15% / 3.82% |
LoseEBS / S&P -3.76% / 2.09% |
LoseEBS / S&P -16.67% / 7.05% |
| 2016-Q32/3 |
WinEBS / S&P 12.13% / 3.85% |
WinEBS / S&P 10.32% / 0.20% |
LoseEBS / S&P -20.00% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | EBS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -28.43% | 20.78% |
| Annualized return | -28.43% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | EBS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -90.67% | 83.14% |
| Annualized return | -37.77% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | EBS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -77.51% | 319.30% |
| Annualized return | -13.86% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |